TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05930028

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Subjects take the investigational products once a day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Subjects take the investigational products once a day for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/Atorvastatin
Description: Subjects take the investigational products once a day for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Atorvastatin
Description: Subjects take the investigational products once a day for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan Placebo
Description: Subjects take the investigational products once a day for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/Atorvastatin Placebo
Description: Subjects take the investigational products once a day for 8 weeks.
Study: NCT05759429

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BWRP
Description: Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BWRP + melatonin
Description: Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
Study: NCT05958771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROTAVAC 5D
Description: monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells. Each dose contains NLT 10 e 5.0 FFU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains all the excipients of ROTAVAC 5D but without the suspension of live attenuated rotavirus
Study: NCT04514744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee bracing
Description: Participants will have one leg immobilized, by means of a removable Don Joy Knee Brace. Participants will be expected to keep the knee brace on for 14 days, completely prevent weight bearing on the immobilized leg, and use crutches.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Resistance Exercise Training
Description: Participants will perform resistance training on 4 occasions throughout an 8 day time period.
Study: NCT06482125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Intravenous Dexmedetomidine
Description: Intervention group will receive Total Intravenous Dexmedetomidine as their anesthetic maintenance agent. Intravenous Dexmedetomidine 1.5ug/kg will be administered within 10 minutes and maintenance dose of 1.5ug/kg/hour continued as the sole anesthetic maintenance agent, thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Sevoflurane
Description: Inhalation Sevoflurane will be administered as an anesthetic maintenance agent. Sevoflurane at 2 - 2.5 Vol% will be administered throughout the operative procedure.
Study: NCT05831839

Intervention type: DEVICE
Group type: OTHER
Intervention: RehaCom
Description: computerized cognitive training

Intervention type: DEVICE
Group type: OTHER
Intervention: RehaCom
Description: computerized cognitive training
Study: NCT05331248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaders in Action: Household Treatment
Description: The Household Treatment (HT) followed a door-to-door delivery approach: CHVs, in coordination with the local Women Emergency Center (CEM), offered 8 treatment sessions to households in the targeted sample. The sessions took place over a period of 1 to 2 months at the residences of the female participants. This intervention was subject to a second-stage randomization to include edutainment videos in its implementation for the HT only treatment arm. In 31 randomly selected HT villages, all targeted households watched the edutainment component as part of the HT program, and in the other 31 HT villages, only 50% of the targeted households were randomly assigned to watch the edutainment component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaders in Action: Household Treatment
Description: The Household Treatment (HT) followed a door-to-door delivery approach: CHVs, in coordination with the local Women Emergency Center (CEM), offered 8 treatment sessions to households in the targeted sample. The sessions took place over a period of 1 to 2 months at the residences of the female participants. This intervention was subject to a second-stage randomization to include edutainment videos in its implementation for the HT only treatment arm. In 31 randomly selected HT villages, all targeted households watched the edutainment component as part of the HT program, and in the other 31 HT villages, only 50% of the targeted households were randomly assigned to watch the edutainment component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaders in Action: Group Treatment
Description: The group-based approach (Group Treatment, or GT) entailed 4 workshops involving various activities and group discussions. The group sessions directed at men had a slightly different curriculum than those directed at women, and always had at least one male CHV in the room facilitating the session. GT sessions took place over one month in each community in village community centers, schools, churches, or other communal spaces where village residents would often gather, and lasted for approximately two hours. The edutainment component was screened in every GT workshop.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaders in Action: Group Treatment
Description: The group-based approach (Group Treatment, or GT) entailed 4 workshops involving various activities and group discussions. The group sessions directed at men had a slightly different curriculum than those directed at women, and always had at least one male CHV in the room facilitating the session. GT sessions took place over one month in each community in village community centers, schools, churches, or other communal spaces where village residents would often gather, and lasted for approximately two hours. The edutainment component was screened in every GT workshop.
Study: NCT05936203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional adjustment
Description: Strategies used to manage glucose control during a prolonged aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of strategies
Description: Strategies used to manage glucose control during a prolonged aerobic exercise
Study: NCT05601921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders. In recent years, TMS studies have been conducted in many painful conditions, which are thought to have complex pain mechanisms in the pathogenesis, and its effectiveness has been reported.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: Sham Repetitive transcranial magnetic stimulation
Study: NCT06305689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical procedure to the gastrocnemius and/or plantar fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: Repeated casts weekly until desired dorsiflexion range achieved
Study: NCT06183086

Intervention type: DEVICE
Intervention: Linovera®
Description: Apply Linovera® at least twice a day (recommended every 12 h) on the pressure ulcer/injury until Category-1 pressure ulcer/injury is healed or until discharge.
Study: NCT03806413

Intervention type: OTHER
Intervention: Open heart surgery
Description: The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
Study: NCT05928715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger feeding
Description: The newborn will receive every expressed breast milk or formula support during the day with the finger feeding method.
Study: NCT05063981

Intervention type: DRUG
Intervention: Mepolizumab
Description: Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control

Intervention type: DRUG
Intervention: Mepolizumab
Description: Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control
Study: NCT04814615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-daratumumab PET/CT
Description: CD38-targeting imaging
Study: NCT05289284

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04764929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Description: Vyatil nonpowered oxygen tent system
Study: NCT05620030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Univentricular Heart
Description: Prevention of complications when discovered
Study: NCT05756543

Intervention type: BEHAVIORAL
Intervention: Counterfactual Inference Test
Description: All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.

Intervention type: BEHAVIORAL
Intervention: Counterfactual Inference Test
Description: All participants were asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
Study: NCT05582213

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: induction of anesthesia
Description: This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: induction of anesthesia
Description: This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram
Study: NCT05744037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: regimen with BTK inhibitor +Anti-CD19 CAR T cells
Description: After FC regimen (fludarabine (25mg/m2/d) on days -5 to -3 and cyclophosphamide (750mg/m2) on days -5) were pretreated, Anti-CD19 CAR T cells were transfused on day 0. The dose was determined by the investigator according to the subjects' own disease conditions and in vitro preparation. Intravenous drip/push at a constant rate for 30 minutes; Ibrutinib, a BTK inhibitor, was enrolled with a standard dose of 560mg qd.
Study: NCT06371729

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEEP mapping
Description: The Substrate-based DEEP Mapping aims to identify the arrhythmogenic substrate of VT in sinus rhythm (SR). A standardized VT mapping and ablation procedure in SR has been proven effective in reducing VT recurrences in a multicenter setting by targeting late potential (LP) abolition. Regions with LPs and LAVAs that displayed decremental behavior evoked during right ventricular (RV) pacing with extra stimuli (decrement-evoked potential; DEEP), colocalized with the regions of the initiation and diastolic pathway of the VT more accurately than those areas displaying non decremental LPs.~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Activation Mapping
Description: VT Activation Mapping can localize reentry circuits, and the diastolic pathway isthmus is the desirable target for ablation when possible because it can eliminate the elements required for reentry. In fact, activation mapping of the entire diastolic pathway is associated with higher freedom from VT recurrences compared to substrate modification~Device use for mapping and ablation procedure:~FlexAbility/Tactiflex/TactiCath Ablation Catheter Sensor Enabled (Abbott, MN), high-density grid mapping catheter (GMC; Advisor HD Grid Mapping Catheter Sensor Enabled, Abbott, MN)
Study: NCT06441032

Intervention type: OTHER
Intervention: No patient treatment is associated with the study
Description: No patient treatment is associated with the study.

Intervention type: OTHER
Intervention: No patient treatment is associated with the study
Description: No patient treatment is associated with the study.
Study: NCT05662059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAVANS
Description: Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RAVANS-sham
Description: RAVANS sham device
Study: NCT05109637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Konectom NMD Application
Description: Administered as specified in the treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Konectom NMD Application
Description: Administered as specified in the treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Konectom NMD Application
Description: Administered as specified in the treatment arm.
Study: NCT06287866

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pinch Graft
Description: In the pinch graft technique, the investigators will numb and then shave off a thin piece of skin and place it in the wound bed.
Study: NCT04319627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin Calcium
Description: Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Each participant will receive the usual treatment for their newly diagnosed blood clot in addition to the intervention they are randomized to.
Study: NCT04902313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awareness and insight Modules (AiM)
Description: 12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Awareness and insight Modules (AiM)
Description: 12 week of daily reflection and meditation exercises, delivered by mobile phone text messages, after 3-4 live introduction sessions.
Study: NCT04429204

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo cryoablation
Study: NCT05693493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proprioceptive knee brace
Description: For the intervention group that randomly consisted of 15 subjects will be using a design of knee brace (Reaction Web®; DonJoy, Vista, CA). The elastomeric web design helps to reduce pain by dispersing load across the knee. The web acts like a spring to absorb shock and shifts the peak loads away from the painful area of the knee. Elastomeric web acts to dynamically stabilise the patella on all sides, bringing the patella into proper tracking position to reduce pain for patients with general patellofemoral instabilities. Reaction Web® has dual-axis hinges that are flexible, creating synergy with the elastomeric web for optimal fit and support, and providing energy dispersion to the knee.
Study: NCT06338293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium
Description: The patients in Inclisiran group were given drugs three times in total. The first needle was injected subcutaneously with 284mg(1.5ml solution) after entering the group, the second needle was injected three months later and the third needle was injected at the ninth month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin
Study: NCT03984019

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac condition measurements
Description: Cardiac MRI, ECG, echocardiography, cardiac blood markers
Study: NCT04555512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive High Intensity Interval Training (PRO-HIIT)
Description: Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves progression of training of 3 stages: 1) six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min; 2) three high-intensity intervals of 2-min separated by two low-intensity intervals of 4-min, and a further 2-min of low intensity following the last interval before cool-down; and 3) three high-intensity intervals of 3-min separated by two low-intensity intervals of 3-min, and a further 1-min of low intensity following last interval before cool-down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Constant High Intensity Interval Training (CON-HIIT)
Description: Individual exercise training sessions, involving two weeks of moderate intensity continuous exercise and 10 weeks of interval exercise training. This protocol involves a constant protocol of training, including six high-intensity intervals (at an RPE of 15-18) of 1-min separated by five low-intensity intervals of 2-min.
Study: NCT06338293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin
Study: NCT04403958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRC
Description: Total wrist arthrodesis with dorsal plate using proximal row of the wrist as bone graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TWA
Description: Total wrist arthrodesis with dorsal plate using iliac crest as bone graft
Study: NCT05694975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: The total dosage of vitamin C for the treatment group is 24 g per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The total dosage of placebo(5% glucose) for the control group is 24 g per day.
Study: NCT04386590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Plus Pulmonary Rehabilitation
Description: Manual therapy combined with Pulmonary Rehabilitation
Study: NCT05017688

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood and stool sample collection
Description: Collection of blood samples (55 mL) Collection of fecal samples (10g)
Study: NCT04386590

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Detuned US plus Pulmonary Rehabilitation
Study: NCT05108584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPE Level 3 and Video Laryngoscope
Description: The operator used level 3 PPE and video laryngoscope for the intubation process

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPE Level 3 and Direct Laryngoscope
Description: The operator used level 3 PPE and direct laryngoscope for the intubation process

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPE Level 2 and Direct Laryngoscope
Description: The operator used level 2 PPE and direct laryngoscope for the intubation process
Study: NCT05653271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1831
Description: Allogeneic gamma delta T (gdT) cell therapy
Study: NCT06058117

Intervention type: OTHER
Intervention: No intervention
Description: no intervention, this is an observational study
Study: NCT05826405

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, it's an observational study
Study: NCT05653271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1831
Description: Allogeneic gamma delta T (gdT) cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Anti-CD20 monoclonal antibody
Study: NCT05657275

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CRP dosage
Description: multimodal algorithm

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: multiplex PCR
Description: multimodal algorithm

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: chest scan without injection
Description: multimodal algorithm